LDB
PVCT

Lee, Danner & Bass’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Lee, Danner & Bass’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$5K – 748
2024
Q3 		$5K Hold
50,000
– – ﹤0.01% 220
2024
Q2 		$6K Buy
+50,000
New +$6K ﹤0.01% 211
2023
Q4 		$5K Hold
50,000
– – ﹤0.01% 205
2023
Q3 		$4K Hold
50,000
– – ﹤0.01% 199
2023
Q2 		$6K Hold
50,000
– – ﹤0.01% 204
2023
Q1 		$8K Hold
50,000
– – ﹤0.01% 196
2022
Q4 		$5K Hold
50,000
– – ﹤0.01% 196
2022
Q3 		$2K Hold
50,000
– – ﹤0.01% 195
2022
Q2 		$3K Hold
50,000
– – ﹤0.01% 194
2022
Q1 		$3K Hold
50,000
– – ﹤0.01% 204
2021
Q4 		$3K Hold
50,000
– – ﹤0.01% 199
2021
Q3 		$3K Hold
50,000
– – ﹤0.01% 198
2021
Q2 		$3K Hold
50,000
– – ﹤0.01% 204
2021
Q1 		$3K Hold
50,000
– – ﹤0.01% 192
2020
Q4 		$3K Hold
50,000
– – ﹤0.01% 185
2020
Q3 		$4K Hold
50,000
– – ﹤0.01% 178
2020
Q2 		$2K Buy
+50,000
New +$2K ﹤0.01% 179

Other funds holding PVCT

HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return
AW
Atlas Wealth Cincinnati, Ohio $334M AUM 11.57% 1-Year Est. Return
ACM
Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return
LIA
LBMC Investment Advisors Brentwood, Tennessee $1.64B AUM 15.26% 1-Year Est. Return
FS
Financial Symmetry Raleigh, North Carolina $300M AUM 23.79% 1-Year Est. Return

Lee, Danner & Bass's PVCT Position: Q4 2024 in Review

Lee, Danner & Bass sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2024, closing a stake of 50,000 shares — an estimated $5K sold.

Lee, Danner & Bass first reported a position in PVCT in Q2 2020 and held it in 17 quarters. The position peaked at $8K in Q1 2023. 6 funds tracked by Wall St. Rank hold PVCT as of Q4 2024.

  • Lee, Danner & Bass reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2024 after selling out during the quarter.
  • Lee, Danner & Bass sold 50,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2024, an estimated $5K.
  • Lee, Danner & Bass first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2020 and held it in 17 quarters.
  • Lee, Danner & Bass's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $8K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2024.

Based on Lee, Danner & Bass's 13F filing for Q4 2024, filed 11 Feb 2025.